Sun Xi, Zhangyuan Guangyan, Shi Liang, Wang Ying, Sun Beicheng, Ding Qiang
Jiangsu Breast Disease Center, the First Affiliated Hospital with Nanjing Medical University Liver Transplantation Center of the First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China.
Medicine (Baltimore). 2017 May;96(19):e6860. doi: 10.1097/MD.0000000000006860.
Cyclin B plays a crucial role in cancer cell cycle progression and is overexpressed in many human cancers, including breast cancer. However, the prognostic value of cyclin B expression in breast cancer is controversial. We performed a meta-analysis to assess the clinicopathological and prognostic significance of cyclin B expression in breast cancer.
We searched PubMed, web of science, and Embase databases to retrieve the publications investigating the association between cyclin B expression and clinicopathological/prognostic significance in breast cancer patients. The pooled hazard ratio (HR) or odds ratio (OR) with its 95% confidence intervals (CIs) were used to estimate the effects.
Ten studies with 2366 breast cancer patients were included to evaluate the association between cyclin B expression and overall survival (OS), disease-free survival (DFS), disease-specific survival (DSS), and clinicopathological parameters. The results showed that cyclin B overexpression in breast cancer patients was significantly associated with both poor OS (univariate analysis: HR = 2.38, 95% CI = 1.72-3.30, P < .001), DFS (univariate analysis: HR = 1.86, 95% CI = 1.50-2.32, P < .001; multivariate analysis: HR = 1.75, 95% CI = 1.22-2.52, P = .003), and DSS (multivariate analysis: HR = 5.42, 95% CI = 2.15-13.66, P < .001). Additionally, cyclin B overexpression was significantly associated with lymphatic invasion (OR = 2.58, 95% CI = 1.03-6.46, P = .017).
Cyclin B overexpression appears to be an independent potential prognostic marker to DSS and DFS for breast cancer. Further studies with large sample size are needed to dissect the relationship between cyclin B and clinicopathological features or prognosis of breast cancer.
细胞周期蛋白B在癌细胞周期进程中起关键作用，且在包括乳腺癌在内的多种人类癌症中过表达。然而，细胞周期蛋白B表达在乳腺癌中的预后价值存在争议。我们进行了一项荟萃分析，以评估细胞周期蛋白B表达在乳腺癌中的临床病理及预后意义。
我们检索了PubMed、科学网和Embase数据库，以获取研究细胞周期蛋白B表达与乳腺癌患者临床病理/预后意义之间关联的出版物。采用合并风险比（HR）或比值比（OR）及其95%置信区间（CI）来估计效应。
纳入了10项研究，共2366例乳腺癌患者，以评估细胞周期蛋白B表达与总生存期（OS）、无病生存期（DFS）、疾病特异性生存期（DSS）及临床病理参数之间的关联。结果显示，乳腺癌患者中细胞周期蛋白B过表达与较差的OS（单因素分析：HR = 2.38，95% CI = 1.72 - 3.30，P <.001）、DFS（单因素分析：HR = 1.86，95% CI = 1.50 - 2.32，P <.001；多因素分析：HR = 1.75，95% CI = 1.22 - 2.52，P =.003）和DSS（多因素分析：HR = 5.42，95% CI = 2.15 - 13.66，P <.001）均显著相关。此外，细胞周期蛋白B过表达与淋巴浸润显著相关（OR = 2.58，95% CI = 1.03 - 6.46，P =.017）。
细胞周期蛋白B过表达似乎是乳腺癌DSS和DFS的一个独立潜在预后标志物。需要进一步开展大样本研究来剖析细胞周期蛋白B与乳腺癌临床病理特征或预后之间的关系。
